Efficacy and Safety of Anrikefon in Haemodialysis Patients with Pruritus: Insights from a Phase 3 Multicentre Randomised Controlled Trial
Posted inClinical Updates Nephrology Specialties Wellness & Lifestyle

Efficacy and Safety of Anrikefon in Haemodialysis Patients with Pruritus: Insights from a Phase 3 Multicentre Randomised Controlled Trial

This phase 3 trial demonstrates that anrikefon significantly reduces pruritus intensity and improves quality of life in patients undergoing haemodialysis with moderate to severe chronic kidney disease-associated pruritus, with a favorable safety profile.